McCullough M, Caraballo C, Ravindra NG, et al. - Since left ventricular assist devices (LVADs) improve outcomes in patients with advanced heart failure, however, the role of neurohormonal blockade (NHB) in treating these patients is not well known, researchers explored the connection between NHB blockade and outcomes in patients with LVADs. The sample consisted of patients from more than 170 centers across the US and Canada with continuous flow LVADs from 2008 to 2016 who were alive with the device in place at 6 months after implant. In total, 12,144 patients in Interagency Registry for Mechanically Assisted Circulatory Support met inclusion criteria, of whom 2,526 were women, 8,088 were white, 3,024 were African American, and 753 were Hispanic. According to findings, continued treatment was related to improved survival and quality of life among patients with LVADs who tolerated NHB therapy. The optimal regimen of heart failure after LVAD implant for patients may be the initiation and continuation of guideline-driven medical therapy.